GlassScriptPhysician profile
Ritu K Talwar
NPI 1518124932
$5,144.27
in general payments reported to CMS, 2019-2025
26 companies · $888 in 2025
The $888 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $508 · 2021: $969 · 2022: $508 · 2023: $855 · 2024: $753 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,464.66 | 2021-2025 | Vraylar |
| Allergan, INC. | $524.51 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $385.24 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $373.37 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $366.21 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $333.43 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.84 | 2021-2025 | Caplyta |
| Lundbeck LLC | $209.58 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $206.05 | 2019-2025 | Spravato |
| Alkermes, INC. | $180.91 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $152.96 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $144.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.87 | 2019-2021 | |
| Bausch Health US, LLC | $79.98 | 2019-2022 | |
| Axsome Therapeutics, INC. | $76.46 | 2023-2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $57.18 | 2022 | |
| Tris Pharma INC | $51.38 | 2023-2025 | Dyanavel Xr |
| Shire North American Group INC | $35.43 | 2019 | |
| Ironshore Pharmaceuticals INC. | $34.86 | 2019-2023 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $23.64 | 2019 | |
| Collegium Pharmaceutical, INC. | $23.40 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $20.94 | 2021 | |
| Neos Therapeutics, LP | $20.36 | 2024 | Adzenys Xr-Odt |
| Indivior INC. | $17.39 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $15.27 | 2023 | Quviviq |
| Pernix Therapeutics Holdings, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.